loading...| Preferred Name |
Brentuximab Vedotin |
|
| Synonyms |
|
|
| Definitions |
An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C66944 |
|
| Accepted_Therapeutic_Use_For |
Hodgkin lymphoma (HL); anaplastic large cell lymphoma (ALCL); other CD30-expressing peripheral T-cell lymphomas |
|
| CAS_Registry |
914088-09-8 |
|
| Chemical_Formula |
C68H106N11O15S |
|
| code |
C66944 |
|
| Contributing_Source |
CTRP FDA PCDC |
|
| definition |
An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells. |
|
| Display_Name |
Brentuximab Vedotin |
|
| FDA_UNII_Code |
7XL5ISS668 |
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C186341 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 http://purl.obolibrary.org/obo/NCIT_C186327 http://purl.obolibrary.org/obo/NCIT_C186328 |
|
| Is_Value_For_GDC_Property | ||
| label |
Brentuximab Vedotin |
|
| Legacy Concept Name |
SGN-35 |
|
| Maps_To |
Brentuximab Vedotin |
|
| NCI_Drug_Dictionary_ID |
530758 |
|
| PDQ_Closed_Trial_Search_ID |
530758 |
|
| PDQ_Open_Trial_Search_ID |
530758 |
|
| Preferred_Name |
Brentuximab Vedotin |
|
| prefixIRI |
NCIT:C66944 |
|
| prefLabel |
Brentuximab Vedotin |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C2932409 |
|
| subClassOf |